ExCellThera

Q: Where is ExCellThera located?

ExCellThera's headquarters are located at 2950 Chemin De Polytechnique, Montreal, Quebec, H3T 1J4, Canada

Q: What is ExCellThera's phone number?

ExCellThera's phone number is (800) 307-6627

Q: What is ExCellThera's official website?

ExCellThera's official website is www.excellthera.com

Q: What is ExCellThera's Revenue?

ExCellThera's revenue is $5.9 Million

Q: What industry does ExCellThera belong to?

ExCellThera is in the industry of: Business Services General , Business Services

Q: What is ExCellThera competition?

ExCellThera top competitors include: Phoenix Molecular Designs , Hemostemix Inc , Morphocell Technologies Inc , Stem Cell Podcast

Q: What technology does ExCellThera use?

Some of the popular technologies that ExCellThera uses are: goo.gl, Gravity Forms, Yoast SEO, Cloudflare CDN

Q: Who is the CEO of ExCellThera?

ExCellThera's CEO is David Millette

Q: How do I contact ExCellThera?

ExCellThera contact info: Phone number: (800) 307-6627 Website: www.excellthera.com

Q: What does ExCellThera do?

ExCellThera is a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellThera's most advanced technology, ECT-001 Cell Therapy, combines a proprietary small m... olecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials. Read More

Business Services · Canada · <25 Employees

ExCellThera is a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies and other diseases. ExCellThera's most advanced technology, ECT-001 Cell Therapy, combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials.Read More

View Company Info for Free

Who is ExCellThera

Headquarters

2950 Chemin De Polytechnique, Montreal, Quebec, H3T 1J4, Canada

Phone Number

(800) 307-6627

Website

www.excellthera.com

Revenue

$5.9M

Industry

Business Services General

Business Services

Is this data correct?

View contact profiles from ExCellThera

Popular SearchesExcellthera IncExcellTheraThera Excel IncSIC Code 87,873NAICS Code 54,541Show More

Top Competitors of ExCellThera

Phoenix Molecular Designs
<25
<$5M
1
Hemostemix Inc
<25
<$5M
2
Morphocell Technologies Inc
<25
<$5M
3
Stem Cell Podcast
<25
<$5M
4
ExVilent Ltd
<25
<$5M
5
Stembrella
<25
<$5M
6

ExCellThera Org Chart

David Millette

Chief Executive Officer

Phone

Anne Marinier

Chemistry Chief Technical Of...

Phone

View Email Formats for ExCellThera

ExCellThera Tech Stack

goo.gl

Gravity Forms

Yoast SEO

Cloudflare CDN

See more technologies

Top Companies in Canada

ExCellThera News & Media

UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting
MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants. In this real-world analysis using matched-controlled data from the CIBMTR® (Center
Dec 12, 2022
www.globenewswire.com
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an optimized culture system to produce unique UM171-expanded stem cell transplants, and it also enabl
Nov 15, 2022
www.globenewswire.com
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological indications, including severe leukemias and myelodysplastic syndromes, in the United States and Canada. Add
Nov 8, 2022
finance.yahoo.com
ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting
MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s most advanced investigational drug, ECT-001 Cell Therapy, has been accepted for oral presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 10-13, 2022. The abstract is now available on the ASH website at www.hematology.org.
Nov 4, 2022
www.globenewswire.com
ExCellThera announces submission of Drug Master File for UM171
MONTRÉAL, June 17, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for UM171, a proprietary molecule being studied for use in the expansion and rejuvenation of hematopoietic stem
Jun 17, 2022
www.globenewswire.com